Fresenius stock stays supported by earnings and margin growth.

Fresenius (ISIN DE0005785604) closed 2025 with EUR 21.5 billion in revenue, up 5% at constant exchange rates, while adjusted net income rose 12% to EUR 1.75 billion. The group also reported a 15.5% adjusted EBIT margin in 2025, and management proposed a dividend of EUR 1.00 per share for the year.

EUR 21.5 billion revenue

Fresenius said 2025 revenue reached EUR 21.5 billion, with 5% constant-currency growth and 8% organic growth. Adjusted EBIT climbed 10% to EUR 3.3 billion, which underpinned the margin improvement to 15.5% from 14.7% a year earlier.

EUR 1.75 billion net income

Adjusted net income for 2025 came in at EUR 1.75 billion, up 12% year on year, while adjusted earnings per share rose 13% to EUR 3.12. Management also said it expected another year of growth in 2026, with constant-currency revenue growth guided at 4% to 6% and adjusted EBIT growth at 3% to 7%.

Clinical care and hospital supply

Fresenius Medical Care remains the group’s largest publicly visible business line, while the Kabi nutrition, infusion, and biosimilars portfolio continues to support recurring demand. In 2025, the company said its four operating segments all contributed to the higher revenue base, which is the main reason the margin story now matters as much as top-line growth.

Dividend and capital use

The proposed dividend of EUR 1.00 per share for 2025 marked another sign of balance-sheet confidence after the year’s profit improvement. For investors, the key comparison is clear: adjusted net income rose 12% while adjusted EPS rose 13%, faster than revenue growth.

Fresenius stock on Xetra

Fresenius stock trades on Xetra under the symbol FRE and carries a market capitalization of EUR 12.7 billion as of 18 July 2026. The stock quote was not included in the available data, so the market view in this article is anchored to the company’s reported 2025 numbers and the current valuation reference.